Cosmo Pharmaceuticals NV
SIX:COPN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
50.9
79.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals NV
Gross Profit
Cosmo Pharmaceuticals NV
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Gross Profit
€145.7m
|
CAGR 3-Years
61%
|
CAGR 5-Years
39%
|
CAGR 10-Years
11%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Gross Profit
$1.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Gross Profit
$3.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Gross Profit
$127m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
28%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cosmo Pharmaceuticals NV
Glance View
Cosmo Pharmaceuticals NV, rooted in the picturesque landscapes of Italy but with its headquarters in Ireland for strategic financial maneuvering, has carved a niche for itself within the global pharmaceuticals industry. This specialty pharmaceutical company is dedicated to the development and manufacturing of therapies for gastrointestinal diseases. Cosmo’s forte lies in its proprietary clinical development platform, providing innovative solutions aimed at enhancing gastrointestinal health, covering conditions like inflammatory bowel disease, colon infections, and bowel preparation for colonoscopy. These critical health areas require specialized treatments, and Cosmo leverages its technological prowess through its novel drug delivery technologies such as Methylene Blue MMX and Aemcolo. This focus not only elevates the scientific community’s understanding of GI issues but positions Cosmo at the intersection of research innovation and practical treatment efficacy. Cosmo Pharmaceuticals thrives on a business model that seeks to maximize the potential of its intellectual property and licensing operations. By investing substantially in research and development, the company brings forward its proprietary products which offer targeted therapies, and then participates in strategic partnerships and licensing agreements with larger pharmaceutical companies. By doing so, Cosmo reduces risk and diversifies its revenue channels. This agile strategy allows them to earn royalties and revenue through commercialization deals, placing them in a financial position of strength without having to shoulder the full burden of global marketing and distribution. The company’s ability to merge scientific ingenuity with strategic business acumen underscores its journey from a regional player to a notable name on the international pharmaceutical stage.
See Also
What is Cosmo Pharmaceuticals NV's Gross Profit?
Gross Profit
145.7m
EUR
Based on the financial report for Jun 30, 2024, Cosmo Pharmaceuticals NV's Gross Profit amounts to 145.7m EUR.
What is Cosmo Pharmaceuticals NV's Gross Profit growth rate?
Gross Profit CAGR 10Y
11%
Over the last year, the Gross Profit growth was 135%. The average annual Gross Profit growth rates for Cosmo Pharmaceuticals NV have been 61% over the past three years , 39% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet